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Abstract: Metachromatic leukodystrophy (MLD) disorder is a rare lysosomal storage disorder 
that leads to severe neurological symptoms and an early death. MLD occurs due to the deficiency 
of enzyme arylsulfatase A (ARSA) in leukocytes, and patients with MLD excrete sulfatide in 
their urine. In this study, the ARSA gene in 12 non-consanguineous MLD patients and 40 healthy 
individuals was examined using polymerase chain reaction sequencing. Furthermore, the 
structural and functional effects of new mutations on ARSA were analyzed using SIFT (sort-
ing intolerant from tolerant), I-Mutant 2, and PolyPhen bioinformatics software. Here, 4 new 
pathogenic homozygous mutations c.585G.T, c.661T.A, c.849C.G, and c.911A.G were 
detected. The consequence of this study has extended the genotypic spectrum of MLD patients, 
paving way to a more effective method for carrier detection and genetic counseling.
Keywords: psychomotor regression, demyelinating, gait abnormality and impairment, metach-
romatic leukodystrophy (MLD), behavioral disturbances
Introduction
Metachromatic leukodystrophy (MLD) is a rare lysosomal storage disorder, caused 
by deficiency of the enzyme arylsulfatase A (ARSA, E.C. 3.1.6.1) with a frequency 
of approximately 1 per 40,000 worldwide.1 ARSA catalyzes initiative step of the 
metabolic pathway, sphingolipid 3′-o-sulfogalactosylceramide, known as sulfatide. 
Sulfatide is especially abundant in the myelin sheath of the nervous system.2 Mutations 
in the ARSA gene (Figure 1) (GenBank accession number NP_000478) could lead to 
a deficiency in ARSA activity, leading to accumulation of sulfatide, especially in the 
nervous system.3,4 This phenomenon causes a progressive demyelination that leads to 
different neurological symptoms including ataxia, an initially flaccid and later spastic 
paresis, optic atrophy, and dementia.5
To date, there is no effective treatment for MLD. However, bone marrow transplanta-
tion and stem cell therapy can be beneficial for patients with juvenile- and adult-onset 
forms in the early stages of the disease. In addition, gene and enzyme replacement thera-
pies for the treatment of MLD have shown promising outcomes in mice models.6–11
ARSA deficiency is divided into 3 clinical subtypes: late-infantile (50%–60%), 
juvenile (20%–30%), and adult (15%–20%). The disorder course may range from 3 
to 10 years or more in the late-infantile type and up to 20 years in the juvenile and 
adult types.9
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Typical magnetic resonance imaging (MRI) alterations 
in MLD have been explained in the literature. T2-weighted 
MRI (T2W MRI) of the brain in MLD patients typically 
indicates butterfly-shaped confluent white matter hyperin-
tensities with early involvement of the corpus callosum.12 
In addition, there is elevated white matter involvement, 
including U-fibers and cerebellar white matter, as well as 
cerebral atrophy with progression of the MLD disease.13–16 
In this study, the ARSA gene was examined in individuals 
who met the proposed clinical criteria for MLD in order to 
identify the pathogenic impact of the associated mutations 
in MLD.
Materials and methods
Patient collection and ethical statement
In this study, 12 Iranian non-consanguineous MLD patients, 
with a mean age of 3.5 years, were diagnosed between January 
2009 and November 2012. Clinical characteristics of MLD 
patients are summarized in Table 1. Blood samples from 
12 MLD patients and 40 healthy individuals were obtained 
from the Special Medical Center (SMC), Tehran, Iran. Written 
informed consent for genetic study and molecular analysis 
and consent to publish results was obtained from the healthy 
controls, patients, and parents on behalf of their children. The 
clinical ethics committee of SMC specifically approved this 
study (Approval No ML-41-1224) in December 2012. The 
exclusion criteria for healthy individuals were any history of 
familial and sporadic cancers, hereditary and non-hereditary 
metabolic disorders, and nuclear and mitochondrial DNA- 
associated disorders.
enzymatic aRsa activity assay
ARSA activity was determined in leukocytes using p-nitrocat-
echol sulfate as described previously by Molzer et al.17
neuroimaging (MRi) analysis
T2-weighted spin-echo sequences of the brain were car-
ried out using a Siemens Magnetom Avanto 1.5 Tesla MRI 
(Munich, Germany). Images were evaluated in a blind fashion 
by a neuroradiologist.
Dna extraction and polymerase chain 
reaction (PCR)
The genomic DNA was extracted from the blood samples 
of MLD patients by the QIAamp DNA Micro Kit (Qiagen 
#56304). PCR primers18 for amplification of exons 1–8 of 
the ARSA gene are as indicated in Table 2. Briefly, PCR 
was carried out in final volumes of 25 µL, containing 
100–200 ng of total genomic DNA, 10 pmol of forward 
and reverse primers, 2.5 mM of MgCl
2
, 200 mM of each 
Figure 1 The ARSA gene maps to chromosome 22q13 covers 3.2 kb of genomic Dna and includes 8 exons.
       
NE5HYHUVHVWUDQG
Table 1 Clinical and biochemical features of 12 iranian MlD patients
Patient no Age  
(years)
Initial manifestation Age of onset 
(years)
Neuropathy Seizures Urine  
sulfatides
ARSA enzyme 
activity (%)
P1 8 gait abnormality 5 Demyelinating + .20† 3
P2 5.5 Behavioral disturbances 4 Demyelinating - .20 2.8
P3 2.5 Psychomotor regression 2 nD - .20 0
P4 2 Psychomotor regression 1 nD + .20 1.1
P5 4 Psychomotor regression 2 Demyelinating - .20 2.5
P6 2 Psychomotor regression 1.5 DTR: absent - .20 1.5
P7 2 Psychomotor regression 1.5 DTR: absent - .20 1.2
P8 2.5 Psychomotor regression 1 nD - .20 2
P9 6 gait impairment 4.5 Demyelinating - .20 2.8
P10 6 Behavioral 4.5 Demyelinating - .20 4
P11 3 gait 2.5 Demyelinating - .20 2.5
P12 4 Psychomotor regression 3 nD - .20 2.8
Note: †Times higher compared to normal.
Abbreviations: MLD, metachromatic leukodystrophy; ND, not determined; DTR, deep tendon reflexes.
 
Th
er
ap
eu
tic
s 
an
d 
Cl
in
ica
l R
isk
 M
an
ag
em
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
11
9.
40
.1
22
.2
15
 o
n 
27
-F
eb
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Therapeutics and Clinical Risk Management 2017:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
727
Four novel ARSA gene mutations
deoxyribonucleoside triphosphates (dNTP), and 1 U of 
super Taq DNA polymerase (Roche Diagnostics, Mannheim, 
Germany). The PCR mixture was cycled for 35 times at 95°C 
for 1 minute; annealing temperature was based on temperature 
(TM) (°C) of forward and reverse primers (Table 2). The PCR 
products were examined on 2% agarose gel electrophoresis 
(Figure 2) in 0.5× Tris-borate-EDTA (TBE) buffer at 110 V 
for 50 minutes, and then stained with 0.002 mg/mL EtBr 
solution and visualized using ultraviolet light.
Dna sequencing and bioinformatics 
analysis
The PCR products were sequenced by forward or reverse 
primers on an ABI 3700 sequencer (Kosar Company, Tehran, 
Iran) and the results were compared using Finch TV program 
and were then analyzed on the NCBI website (http://blast.
ncbi.nlm.nih.gov/Blast.cgi). Moreover, the target sequence 
of patient was compared with normal reference sequence and 
ARSA gene mutations in exons and the splicing sites of the 
introns were identified. The functional and structural impacts 
of identified novel mutations in ARSA gene were assessed 
using in silico prediction algorithms including SIFT,19 
PolyPhen-2,20 and I-Mutant 2.0 (http://folding.biofold.org/ 
i-mutant/i-mutant2.0.html).
statistical analysis
The chi-square test was used with Statistical Package for 
the Social Sciences (version 13) to examine the associa-
tion between patient and healthy control samples, whereas 
P-value ,0.05 was considered statistically significant.
Results
At T2W MRI, MLD patients demonstrated symmetric con-
fluent areas of high signal intensity in the periventricular 
white matter (Figure 3: arrows in A–C) with sparing of the 
subcortical U-fibers (Figure 3: arrows in A). No enhance-
ment is evident in computed tomography or MRI. The 
tigroid (Figure 3: arrows in D) and leopard skin (Figure 3: 
arrows in E and F) patterns of demyelination, suggesting 
sparing of the perivascular white matter, are identified in 
the periventricular white matter and centrum semiovale. The 
corpus callosum, corticospinal, and internal capsule tracts are 
also frequently involved. The cerebellar white matter may 
appear hyperintense at T2W MRI. In the later step of MLD, 
corticosubcortical atrophy is often ascertained, particularly 
after involvement of the subcortical white matter.
Eight exons of the ARSA gene were examined in 12 
patients with MLD symptoms. The c.100G.A homozygous 
mutation in exon 1, c.661T.A homozygous mutation 
in exon 3, c.739G.A homozygous mutation in exon 4, 
c.827C.T homozygous mutation in exon 4, c.911A.G 
homozygous mutation in exon 5, c.931G.A homozygous 
mutation in exon 5, c.849C.G homozygous mutation in 
Figure 2 agarose gel electrophoresis of PCR product. The presence of PCR 
products was confirmed by analyzing the products on a 2% agarose gel. From left: 
lane 1: exon 1 (405 bp), lane 2: exon 1–2 (737 bp), lane 3: exon 2*–4 (706 bp), 
lane 4: exon 5–7* (860 bp), lane 5: exon 7–8 (916 bp), lane 6: Dna ladder (Thermo 
Scientific Gene Ruler 100 bp #SM0241/2/3).
Abbreviation: PCR, polymerase chain reaction.
     /DGGHU
Table 2 PCR primers for amplification of ARSA gene in MlD patients
Primers Exon Primer sequence (5′–3′) Amplicon 
size (bp)
TM (°C)
1 1 F: TCggggagTaTTTgggTC
R: gCaaTCCaTTgggaggaaag
405 57
2 1*–2 F: TTgCCCgTCCgCCCaaCaTCgTg
R: CCCTggTCaCagCCaCCgTCgCaag
737 68
3 2*–4 F: gaTTTCTaggCaTCCCgTaCTC
R: CCCTCaCCCaCTaTgTTCTTg
706 62
4 5–7* F: gCCaagaaCaTagTgggTgagg
R: ggTagaagaagagagaCTgCCgag
860 62
5 7–8 F: gCaagaagCggTgCaCgTCC
R: CCaCgaCaCCagggTTCaaaTCC
916 63
Note: *Due to the large size of exons 1, 2, and 7, they are divided into 2 overlapping fragments.
Abbreviations: TM, temperature; PCR, polymerase chain reaction; MlD, meta chromatic leukodystrophy; F, forward; R, reverse.
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Table 3 Mutations in the ARSA gene in iranian MlD patients
Nucleotide  
change
Amino acid  
change
Location Mutation  
type
Status References
c.100g.a p.g34s exon 1 Missense homo (1)* 21
c.585G.T p.W195C exon 3 Missense homo (1) not reported
c.661T.A p.F221I exon 3 Missense homo (1) not reported
c.736C.T p.R246C exon 4 Missense homo (1) 22
c.739g.a p.g247R exon 4 Missense homo (1) 23
c.827C.T p.T276M exon 4 Missense homo (1) 24
c.849C.G p.D283E exon 4 Missense homo (1) not reported
c.911A.G p.K304R exon 5 Missense homo (1) not reported
c.931g.a p.g311s exon 5 Missense homo (2) 25
g.a c.978+1g.a – splicing homo (1) 27
a.g a.g 96 relative to  
termination codon
– Regulatory homo (1) 26
Notes: *The number in parentheses in the status column shows the number of patients; new mutations are shown in bold.
Abbreviation: MlD, metachromatic leukodystrophy.
Figure 3 axial T2-weighted brain MRi from patient P9.
Notes: The area with arrows represents of high signal intensity in the periventricular white matter (A–C) with sparing of the subcortical U-fibers (arrows), the tigroid (D) 
and leopard skin patterns of demyelination (E and F).
Abbreviations: MRi, magnetic resonance imaging; P9, patient 9.
exon 4, A.G 96 relative to termination codon homozy-
gous mutation, W195C homozygous mutation in exon 3, 
and c.978+1G.A homozygous mutation in intron 5 were 
detected as presented in Table 3. The 4 new mutations 
c.585G.T, c.661T.A, c.849C.G, and c.911A.G were 
significantly (P,0.05) identified in 4 patients (Table 4 and 
Figure 4A–D). The possible structural and functional effects 
of identified new mutations in ARSA were examined using the 
bioinformatics SIFT, PolyPhen, and I-Mutant 2.0 software. 
Here, SIFT outcomes showed that W195C, F221I, D283E, 
and K340R mutations were determined as deleterious with 
scores of -0.734, -5.852, -3.908, and -2.931, respectively. 
I-Mutant analysis, based on the free energy change value 
(sign of DDG), demonstrated that p.W195C, p.F221I, 
p.D283E, and p.K340R mutations decreased protein sta-
bility. According to the PolyPhen score, the c.585G.T, 
c.661T.A, c.849C.G, and c.911A.G mutations were 
determined as probably damaging the protein structure 
and function with scores of 0.994, 1.000, 1.000 and 1.000, 
respectively (Table 4).
 
Th
er
ap
eu
tic
s 
an
d 
Cl
in
ica
l R
isk
 M
an
ag
em
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
11
9.
40
.1
22
.2
15
 o
n 
27
-F
eb
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Therapeutics and Clinical Risk Management 2017:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
729
Four novel ARSA gene mutations
Table 4 statistical and bioinformatics analysis of 4 novel pathogenic mutations
Patient no Novel 
mutations
Statistical analysis Bioinformatics analysis
P-value PolyPhen 2 SIFT I-Mutant 2.0
Prediction Score Prediction Score Prediction (DDG)
P12 W195C ,0.05 Probably damaging 0.994 Deleterious -0.734 Decrease stability
P2 F221i ,0.05 Probably damaging 1 Deleterious -5.852 Decrease stability
P8 D283e ,0.05 Probably damaging 1 Deleterious -3.908 Decrease stability
P6 K304R ,0.05 Probably damaging 1 Deleterious -2.931 Decrease stability
Notes: novel pathogenic mutations were examined using 3 computational methods to assess the structural and functional impacts of novel amino acid changes: PolyPhen 2 
(benign or damaging), siFT (tolerated or deleterious), and i-Mutant 2.0 (increase or decrease stability). PolyPhen prediction score: benign (#0.5) and probably damaging (0.5,). 
siFT prediction score: tolerated ($0.05) and deleterious (#0.05). i-Mutant 2.0 prediction: Free energy change value (DDg): decreasing or increasing protein stability.
Abbreviations: siFT, sorting intolerant from tolerant; DDg, the predicted free energy change value.
Figure 4 Dna sequencing result of the ARSA gene. (A) sequence with a new g.T homo W195C mutation (patient 12). (B) sequence with a new T.a homo F221i 
mutation (patient 2). (C) sequence with a new C.g homo D283e mutation (patient 8). (D) sequence with a new a.g homo K304R mutation (patient 6).
& & & & 7 * 7 & 7 * & & & * & & & & &7 7 7 7& 7* $$
$ $ $& $ $ $ $ $* * ** * * 7 7  7 7 ** * * * * *
$ %
& '
Discussion
In this study, 4 novel pathogenic mutations including c.585G.T, 
c.661T.A, c.849C.G, and c.911A.G in the ARSA gene 
were identified among 12 unrelated Iranian MLD patients. 
The previous reported mutations including the c.100G.A muta-
tion in patient 1 (P1), c.736C.T mutation in P3, c.739G.A 
mutation in P4, c.827C.T mutation in P5, c.931G.A 
mutation in P7 and P9, A.G 96 relative to the termination 
codon in P15, and c.978+1G.A mutation in P11 that were 
reported by Gort et al,21 Gieselmann et al,22 Hasegawa et al,23 
Harvey et al,24 Kreysing et al,25 Gieselmann et al,26 and Eng et al,27 
respectively.
Hence, additional research is required to affirm the 
biological role of these pathogenic mutations and confirm 
the in silico bioinformatics findings that have shown possible 
effects on protein structure and/or function in the absence 
of the ARSA enzyme.
The ARSA gene has 8 exons, which are located on 
chromosome 22 (22q13.33).25 At present, more than 150 
mutations were identified in the ARSA gene according to the 
Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/
ac/gene.php?gene=ARSA) (Figure 5).
MLD is a heterogeneous disease with 3 frequent defec-
tive alleles including a missense mutation that leads to a 
Ilel79Ser substitution, a splice donor-site mutation at the 
exon 2/intron 2 border, and a missense mutation that causes 
a Pro246Leu substitution, which account for 12%, 25% 
(among European patients), and 25% of all defective alleles, 
respectively.28,29 Other mutant alleles were reported in only 
a few or single patients.30
Conclusion
The result of this research has broadened the genotypic 
spectrum of Iranian patients with MLD, paving way to a more 
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effective method for career detection, genetic diagnosis, and 
counseling of Iranian patients with MLD disorder.
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Note: Reproduced from hgMD® [database on the internet]. Cardiff, UK: Cardiff University. available from: http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ARSa. accessed 
april 4, 2017.31
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